13F Holdings
中文EN

IVF INVO Fertility, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1417926 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.2%
TTM net income YoY82.9%
TTM EPS YoY138.9%
Revenue 3-yr CAGR61.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-72.2%
Net margin-59.9%
FCF margin—
EBITDA margin-64.6%

Returns

ROE-40.5%
ROA-21.6%
ROIC (approx.)-34.7%
Asset turnover0.36x

Leverage & solvency

Liabilities / assets29.4%
Debt / equity0.05x
Current ratio1.00x
Interest coverage-5.06x

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6.84M$6.53M$3.02M$822,196$4.16M
Cost of revenue$30,571$12,201$1.97M$331,523$145,052
Gross profit$6.81M$6.52M$1.05M$490,673$4.02M
R&D expense—$4,880$165,945$544,043$216,430
SG&A expense$7.69M$8.07M$7.49M$9.98M$9.02M
Operating income-$7.24M-$6.63M-$6.77M-$10.63M-$5.22M
Interest expense$1.30M$1.04M$925,909$59,445$1.27M
Pretax income-$5.49M-$7.60M-$8.01M-$10.89M-$6.65M
Income tax-$150,371$140,202$27,786$2,872$4,764
Net income-$23.32M-$9.26M-$8.03M-$10.89M-$6.65M
EBITDA-$6.56M-$5.71M-$6.57M-$10.55M-$5.19M
EPS (basic)-214.64-3,782.65-67.37-17.97-0.63
EPS (diluted)-214.64-3,782.65-67.37-17.97-0.63
Weighted avg. shares (diluted)117,0832,514119,264606,13010.63M
Balance sheet
Cash & equivalents$0$619,520$232,424$90,135$5.68M
Receivables$217,263$113,108$140,550$77,149$50,470
Inventory$225,253$219,764$264,507$263,602$287,773
Current assets$2.76M$1.26M$1.26M$621,087$6.31M
PP&E, net$386,165$466,684$826,418$436,729$501,436
Goodwill$5.88M$5.88M$5.88M——
Intangibles$1.33M$3.28M$4.09M—$132,093
Total assets$20.22M$46.08M$18.51M$3.71M$9.99M
Current liabilities$10.33M$17.87M$8.00M$3.34M$1.17M
Short-term debt$1.27M$6.34M———
Long-term debt$744,725$1.13M———
Total debt$2.02M$7.47M———
Total liabilities$13.00M$26.04M$17.61M$4.69M$2.68M
Shareholders' equity$7.22M$12.58M$892,825-$977,612$7.31M
Net debt$2.02M$6.85M———
Shares outstanding119,3583,111207,711608,61111.93M
Cash flow statement
Operating cash flow-$7.01M-$2.97M-$4.76M-$6.60M-$6.03M
Capital expenditure$43,412$183,703$444,722$10,785$415,710
Free cash flow-$7.06M-$3.16M-$5.20M-$6.61M-$6.45M
Investing cash flow-$2.75M$363,895-$2.49M-$81,217-$2.15M
Financing cash flow$11.10M$3.12M$7.39M$1.09M$3.77M
Depreciation & amortization$677,364$919,603$200,894$77,301$27,760
Stock-based compensation$162,920——$1.62M$1.54M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.